Turn Therapeutics (TTRX) Equity Average (2024 - 2026)

Turn Therapeutics' Equity Average history runs 3 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 1584.8% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 1584.8% YoY), while the FY2025 annual figure was $2.3 million, changed N/A from the prior year.
• Equity Average was $5.4 million for Q1 2026 at Turn Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $5.4 million in Q1 2026 to a low of -$295865.5 in Q4 2024.
• Historically, Equity Average has averaged $1.7 million across 3 years, with a median of $661364.5 in 2025.
• The sharpest annual moves came in 2025 and 2026: Equity Average soared 977.21% in 2025, then soared 1584.8% in 2026.
• A 3-year view of Equity Average shows it stood at -$295865.5 in 2024, then jumped by 977.21% to $2.6 million in 2025, then soared by 108.15% to $5.4 million in 2026.
• The last three Equity Average figures came in at $5.4 million (Q1 2026), $2.6 million (Q4 2025), and $661364.5 (Q3 2025), per Business Quant data.